Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment.
Identifieur interne : 000025 ( PubMed/Corpus ); précédent : 000024; suivant : 000026Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment.
Auteurs : Sydney Rosen ; Bruce Larson ; Alana Brennan ; Lawrence Long ; Matthew Fox ; Constance Mongwenyana ; Mpefe Ketlhapile ; Ian SanneSource :
- PloS one [ 1932-6203 ] ; 2010.
English descriptors
- KwdEn :
- Acquired Immunodeficiency Syndrome (drug therapy), Acquired Immunodeficiency Syndrome (economics), Adolescent, Adult, Anti-HIV Agents (economics), Anti-HIV Agents (therapeutic use), Cohort Studies, Female, HIV Infections (drug therapy), HIV Infections (economics), HIV Infections (immunology), Humans, Male, Middle Aged, South Africa, Treatment Outcome, Young Adult.
- MESH :
- chemical , economics : Anti-HIV Agents.
- geographic : South Africa.
- drug therapy : Acquired Immunodeficiency Syndrome, HIV Infections.
- economics : Acquired Immunodeficiency Syndrome, HIV Infections.
- immunology : HIV Infections.
- chemical , therapeutic use : Anti-HIV Agents.
- Adolescent, Adult, Cohort Studies, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult.
Abstract
Although the medical outcomes of antiretroviral therapy (ART) for HIV/AIDS are well described, less is known about how ART affects patients' economic activities and quality of life, especially after the first year on ART. We assessed symptom prevalence, general health, ability to perform normal activities, and employment status among adult antiretroviral therapy patients in South Africa over three full years following ART initiation.
DOI: 10.1371/journal.pone.0012731
PubMed: 20856821
Links to Exploration step
pubmed:20856821Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment.</title><author><name sortKey="Rosen, Sydney" sort="Rosen, Sydney" uniqKey="Rosen S" first="Sydney" last="Rosen">Sydney Rosen</name><affiliation><nlm:affiliation>Boston University Center for Global Health and Development, Boston, Massachusetts, United States of America. sbrosen@bu.edu</nlm:affiliation></affiliation></author><author><name sortKey="Larson, Bruce" sort="Larson, Bruce" uniqKey="Larson B" first="Bruce" last="Larson">Bruce Larson</name></author><author><name sortKey="Brennan, Alana" sort="Brennan, Alana" uniqKey="Brennan A" first="Alana" last="Brennan">Alana Brennan</name></author><author><name sortKey="Long, Lawrence" sort="Long, Lawrence" uniqKey="Long L" first="Lawrence" last="Long">Lawrence Long</name></author><author><name sortKey="Fox, Matthew" sort="Fox, Matthew" uniqKey="Fox M" first="Matthew" last="Fox">Matthew Fox</name></author><author><name sortKey="Mongwenyana, Constance" sort="Mongwenyana, Constance" uniqKey="Mongwenyana C" first="Constance" last="Mongwenyana">Constance Mongwenyana</name></author><author><name sortKey="Ketlhapile, Mpefe" sort="Ketlhapile, Mpefe" uniqKey="Ketlhapile M" first="Mpefe" last="Ketlhapile">Mpefe Ketlhapile</name></author><author><name sortKey="Sanne, Ian" sort="Sanne, Ian" uniqKey="Sanne I" first="Ian" last="Sanne">Ian Sanne</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20856821</idno><idno type="pmid">20856821</idno><idno type="doi">10.1371/journal.pone.0012731</idno><idno type="wicri:Area/PubMed/Corpus">000025</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000025</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment.</title><author><name sortKey="Rosen, Sydney" sort="Rosen, Sydney" uniqKey="Rosen S" first="Sydney" last="Rosen">Sydney Rosen</name><affiliation><nlm:affiliation>Boston University Center for Global Health and Development, Boston, Massachusetts, United States of America. sbrosen@bu.edu</nlm:affiliation></affiliation></author><author><name sortKey="Larson, Bruce" sort="Larson, Bruce" uniqKey="Larson B" first="Bruce" last="Larson">Bruce Larson</name></author><author><name sortKey="Brennan, Alana" sort="Brennan, Alana" uniqKey="Brennan A" first="Alana" last="Brennan">Alana Brennan</name></author><author><name sortKey="Long, Lawrence" sort="Long, Lawrence" uniqKey="Long L" first="Lawrence" last="Long">Lawrence Long</name></author><author><name sortKey="Fox, Matthew" sort="Fox, Matthew" uniqKey="Fox M" first="Matthew" last="Fox">Matthew Fox</name></author><author><name sortKey="Mongwenyana, Constance" sort="Mongwenyana, Constance" uniqKey="Mongwenyana C" first="Constance" last="Mongwenyana">Constance Mongwenyana</name></author><author><name sortKey="Ketlhapile, Mpefe" sort="Ketlhapile, Mpefe" uniqKey="Ketlhapile M" first="Mpefe" last="Ketlhapile">Mpefe Ketlhapile</name></author><author><name sortKey="Sanne, Ian" sort="Sanne, Ian" uniqKey="Sanne I" first="Ian" last="Sanne">Ian Sanne</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acquired Immunodeficiency Syndrome (drug therapy)</term><term>Acquired Immunodeficiency Syndrome (economics)</term><term>Adolescent</term><term>Adult</term><term>Anti-HIV Agents (economics)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Cohort Studies</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (economics)</term><term>HIV Infections (immunology)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>South Africa</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>South Africa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Acquired Immunodeficiency Syndrome</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Acquired Immunodeficiency Syndrome</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although the medical outcomes of antiretroviral therapy (ART) for HIV/AIDS are well described, less is known about how ART affects patients' economic activities and quality of life, especially after the first year on ART. We assessed symptom prevalence, general health, ability to perform normal activities, and employment status among adult antiretroviral therapy patients in South Africa over three full years following ART initiation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20856821</PMID><DateCreated><Year>2010</Year><Month>09</Month><Day>21</Day></DateCreated><DateCompleted><Year>2011</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment.</ArticleTitle><Pagination><MedlinePgn>e12731</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0012731</ELocationID><ELocationID EIdType="pii" ValidYN="Y">e12731</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although the medical outcomes of antiretroviral therapy (ART) for HIV/AIDS are well described, less is known about how ART affects patients' economic activities and quality of life, especially after the first year on ART. We assessed symptom prevalence, general health, ability to perform normal activities, and employment status among adult antiretroviral therapy patients in South Africa over three full years following ART initiation.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">A cohort of 855 adult pre-ART patients and patients on ART for <6 months was enrolled and interviewed an average of 4.4 times each during routine clinic visits for up to three years after treatment initiation using an instrument designed for the study. The probability of pain in the previous week fell from 74% before ART initiation to 32% after three years on ART, fatigue from 66% to 12%, nausea from 28% to 4%, and skin problems from 55% to 10%. The probability of not feeling well physically yesterday fell from 46% to 23%. Before starting ART, 39% of subjects reported not being able to perform their normal activities sometime during the previous week; after three years, this proportion fell to 10%. Employment rose from 27% to 42% of the cohort. Improvement in all outcomes was sustained over 3 years and for some outcomes increased in the second and third year.</AbstractText><AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">Improvements in adult ART patients' symptom prevalence, general health, ability to perform normal activities, and employment status were large and were sustained through the first three years on treatment. These results suggest that some of the positive economic and social externalities anticipated as a result of large-scale treatment provision, such as increases in workforce participation and productivity and the ability of patients to carry on normal lives, may indeed be accruing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Sydney</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Boston University Center for Global Health and Development, Boston, Massachusetts, United States of America. sbrosen@bu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Alana</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mongwenyana</LastName><ForeName>Constance</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ketlhapile</LastName><ForeName>Mpefe</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sanne</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01CA122930</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057098</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PEPFAR 13</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA122930</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 NS065661</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS057098</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01AI083097</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AI083097</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30NS065661</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2009 Nov;21(11):1343-56</RefSource><PMID Version="1">20024710</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2010 Feb 20;24(4):563-72</RefSource><PMID Version="1">20057311</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2010 Feb;22(2):137-45</RefSource><PMID Version="1">20390492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2005 Jul 15;41(2):217-24</RefSource><PMID Version="1">15983918</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2005 Jul;17(5):579-88</RefSource><PMID Version="1">16036244</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2006 May 12;20(8):1181-9</RefSource><PMID Version="1">16691070</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Nov 12;22(17):2303-11</RefSource><PMID Version="1">18981769</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>S Afr Med J. 2007 Jul;97(7):524-9</RefSource><PMID Version="1">17805455</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2007 Oct 16;4(10):e298</RefSource><PMID Version="1">17941716</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Jul;22 Suppl 1:S131-9</RefSource><PMID Version="1">18664945</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Int Assoc Physicians AIDS Care (Chic). 2008 Jul-Aug;7(4):200-7</RefSource><PMID Version="1">18626120</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Nov 12;22(17):2291-302</RefSource><PMID Version="1">18981768</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2007 May;19(5):626-36</RefSource><PMID Version="1">17505923</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000163" MajorTopicYN="N">Acquired Immunodeficiency Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC2939080</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>05</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>08</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20856821</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0012731</ArticleId><ArticleId IdType="pmc">PMC2939080</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000025 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000025 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:20856821
|texte= Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20856821" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |